Litcius/Paper detail

Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)

Lai Wei, Guiqiang Wang, Negar N. Alami, Wen Xie, Jeong Heo, Qing Xie, Mingxiang Zhang, Yoon Jun Kim, Seng Gee Lim, Linda Fredrick, Wenjing Lü, Wei Liu, Hari V. Kalluri, Preethi Krishnan, Rakesh Tripathi, N. Mobashery, Margaret Burroughs, Armen Asatryan, Jidong Jia, Jinlin Hou

2020˜The œLancet. Gastroenterology & hepatology54 citationsDOI

Topics & Concepts

Internal medicineCirrhosisMedicinePlaceboHepatitis C virusGastroenterologyVirusImmunologyPathologyAlternative medicineHepatitis C virus researchHIV/AIDS drug development and treatmentRenal Transplantation Outcomes and Treatments
Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2) | Litcius